Table 5.
Canonical pathways modulated in normal prostate tissue in 16 men with low-risk prostate cancer who performed vigorous physical activity for ≥3 h/wk. Canonical pathways with unadjusted p-value <0.05 were considered statistically significant. Genes present in our dataset belonging to significant canonical pathways are listed. Adjustment for multiple comparisons was also performed in IPA using the Benjamini-Hochberg method to assess false discovery rate (FDR).
| Canonical Pathways | Genes | Unadjusted p-value |
FDR |
|---|---|---|---|
| Regulation of Actin-based Motility by Rho | MYL9,ACTA2,PPP1R12B,ACTG2 | 0.0001 | 0.0044 |
| Integrin Signaling | MYL9,PARVA,ACTA2,PPP1R12B,ACTG2 | 0.0001 | 0.0051 |
| RhoA Signaling | MYL9,ACTA2,PPP1R12B,ACTG2 | 0.0002 | 0.0055 |
| Cellular Effects of Sildenafil (Viagra) | MYL9,ACTA2,PPP1R12B,ACTG2 | 0.0003 | 0.0056 |
| Tryptophan Degradation X (Mammalian, via Tryptamine) | MAOB,ALDH1A3 | 0.0008 | 0.0100 |
| Putrescine Degradation III | MAOB,ALDH1A3 | 0.0008 | 0.0100 |
| RhoGDI Signaling | MYL9,ACTA2,PPP1R12B,ACTG2 | 0.0010 | 0.0107 |
| ILK Signaling | MYL9,PARVA,ACTA2,ACTG2 | 0.0011 | 0.0112 |
| Dopamine Degradation | MAOB,ALDH1A3 | 0.0013 | 0.0115 |
| Actin Cytoskeleton Signaling | MYL9,ACTA2,PPP1R12B,ACTG2 | 0.0020 | 0.0135 |
| LPS/IL-1 Mediated Inhibition of RXR Function | MAOB,ALDH1A3,FABP1,ABCC4 | 0.0020 | 0.0135 |
| Paxillin Signaling | PARVA,ACTA2,ACTG2 | 0.0020 | 0.0135 |
| Sorbitol Degradation I | SORD | 0.0026 | 0.0151 |
| Signaling by Rho Family GTPases | MYL9,ACTA2,PPP1R12B,ACTG2 | 0.0027 | 0.0151 |
| Noradrenaline and Adrenaline Degradation | MAOB,ALDH1A3 | 0.0030 | 0.0158 |
| Mechanisms of Viral Exit from Host Cells | ACTA2,ACTG2 | 0.0047 | 0.0234 |
| Epithelial Adherens Junction Signaling | MYL9,ACTA2,ACTG2 | 0.0059 | 0.0263 |
| MSP-RON Signaling Pathway | ACTA2,ACTG2 | 0.0059 | 0.0263 |
| Tight Junction Signaling | MYL9,ACTA2,ACTG2 | 0.0069 | 0.0288 |
| Serotonin Degradation | MAOB,ALDH1A3 | 0.0072 | 0.0288 |
| Melatonin Degradation II | MAOB | 0.0102 | 0.0355 |
| NAD Biosynthesis III | NMNAT2 | 0.0102 | 0.0355 |
| NRF2-mediated Oxidative Stress Response | ACTA2,ACTG2,ABCC4 | 0.0105 | 0.0355 |
| Remodeling of Epithelial Adherens Junctions | ACTA2,ACTG2 | 0.0123 | 0.0389 |
| Agrin Interactions at Neuromuscular Junction | ACTA2,ACTG2 | 0.0129 | 0.0389 |
| NAD Salvage Pathway III | NMNAT2 | 0.0129 | 0.0389 |
| Caveolar-mediated Endocytosis Signaling | ACTA2,ACTG2 | 0.0148 | 0.0427 |
| NAD Biosynthesis from 2-amino-3-carboxymuconate Semialdehyde | NMNAT2 | 0.0155 | 0.0437 |
| TR/RXR Activation | NRGN,NCOA3 | 0.0200 | 0.0525 |
| FAK Signaling | ACTA2,ACTG2 | 0.0204 | 0.0525 |
| Crosstalk between Dendritic Cells and Natural Killer Cells | ACTA2,ACTG2 | 0.0214 | 0.0525 |
| Virus Entry via Endocytic Pathways | ACTA2,ACTG2 | 0.0219 | 0.0525 |
| VEGF Signaling | ACTA2,ACTG2 | 0.0219 | 0.0525 |
| Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes | ACTA2,ACTG2 | 0.0240 | 0.0550 |
| Histamine Degradation | ALDH1A3 | 0.0302 | 0.0692 |
| NAD biosynthesis II (from tryptophan) | NMNAT2 | 0.0331 | 0.0708 |
| Fatty Acid α-oxidation | ALDH1A3 | 0.0331 | 0.0708 |
| Phenylalanine Degradation IV (Mammalian, via Side Chain) | MAOB | 0.0355 | 0.0741 |
| Oxidative Ethanol Degradation III | ALDH1A3 | 0.0380 | 0.0759 |
| Ethanol Degradation IV | ALDH1A3 | 0.0427 | 0.0832 |
| Cdc42 Signaling | MYL9,PPP1R12B | 0.0437 | 0.0832 |
| Aryl Hydrocarbon Receptor Signaling | ALDH1A3,NCOA3 | 0.0457 | 0.0851 |
| Hepatic Fibrosis / Hepatic Stellate Cell Activation | MYL9,ACTA2 | 0.0479 | 0.0891 |